Point72 Europe London LLP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Point72 Europe London LLP bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to its most recent filing with the SEC. The firm bought 267,649 shares of the biotechnology company’s stock, valued at approximately $1,654,000. Point72 Europe London LLP owned approximately 0.13% of BioCryst Pharmaceuticals as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 9.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,594,436 shares of the biotechnology company’s stock valued at $9,551,000 after buying an additional 133,629 shares during the last quarter. Norges Bank purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $13,278,000. Capstone Investment Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $112,000. Rafferty Asset Management LLC boosted its position in BioCryst Pharmaceuticals by 18.3% in the fourth quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock valued at $5,724,000 after buying an additional 147,699 shares during the last quarter. Finally, Kynam Capital Management LP increased its holdings in BioCryst Pharmaceuticals by 46.8% in the 4th quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company’s stock worth $27,554,000 after buying an additional 1,466,807 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of research reports. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities boosted their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $7.55 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -7.06 and a beta of 1.88. The stock has a 50 day simple moving average of $7.81 and a 200-day simple moving average of $6.40.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.11. The company had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. During the same period in the previous year, the business earned ($0.24) earnings per share. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.